May 9 – 11, 2023 | Boston, MA

The 4th STING & TLR Targeting Therapies Summit is the only industry-focused meeting dedicated to the development and progression of innate immune-stimulating agonists, taking place for the first time ever in person, in Boston next May.

Facilitating key conversations needed to advance the field, this summit will feature leading companies and organizations like Regeneron, Sumitomo Pharma Oncology, 7&8 Biopharma, Elicio Therapeutics, ImmuneSensor, OncoNano Medicine, and many more, who will address significant topics such as delivery, combinations, toxicity, and cancer vaccines.

The 2023 program will focus on the safe and potent activation of these immune sensors to enhance the effectiveness of your therapies while providing innovative scientific insights to broaden your understanding of PRR activation. Additionally, you can deep dive beyond oncology and explore the use of innate agonists and antagonists to treat infectious diseases and address inflammation, to provide a more holistic view of STING and TLR activation.

“Great opportunity to hear from and interact with other thought leaders of how to advance these critical and promising immune stimulatory medicines to cancer patients in high need of additional treatment options” – Takeda Oncology